Gallant Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Gallant Therapeutics's estimated annual revenue is currently $8.8M per year.
- Gallant Therapeutics's estimated revenue per employee is $147,250
Employee Data
- Gallant Therapeutics has 60 Employees.
- Gallant Therapeutics grew their employee count by 20% last year.
Gallant Therapeutics's People
| Name | Title | Email/Phone |
|---|
Gallant Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 8 | 0% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 17 | 31% | N/A | N/A |
What Is Gallant Therapeutics?
Gallant Therapeutics is a clinical-stage animal health biotechnology company setting a new standard in animal health by harnessing the power of stem cell therapy to treat the root cause of diseases in dogs and cats. Our pipeline of off-the-shelf mesenchymal stem cell (MSC) therapies has the potential to treat a broad range of diseases, including canine and feline osteoarthritis (OA), feline chronic kidney disease (CKD), and others. The first product based on our uterine-derived platform for feline chronic gingivostomatitis (FCGS), is on track for conditional approval by the FDA in 2025. United by a love of and commitment to animals, Gallant’s team includes industry pioneers in veterinary regenerative medicine with deep experience in cell therapy product development, manufacturing and commercialization.
keywords:N/A
N/A
Total Funding
60
Number of Employees
$8.8M
Revenue (est)
20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in SAN DIEGO
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $5.5M | 60 | 22% | N/A |
#2 | $17.8M | 60 | 0% | N/A |
#3 | $7.8M | 60 | N/A | N/A |
#4 | $11.3M | 60 | N/A | N/A |
#5 | $7.5M | 60 | N/A | N/A |